請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43988完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林大盛 | |
| dc.contributor.author | Li-En Hsieh | en |
| dc.contributor.author | 謝立恩 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:35:17Z | - |
| dc.date.available | 2014-08-20 | |
| dc.date.copyright | 2009-08-20 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-13 | |
| dc.identifier.citation | Addie, D.D., Jarrett, O., 1992, A study of naturally occurring feline coronavirus infections in kittens. Vet Rec 130, 133-137.
Addie, D.D., Kennedy, L.J., Ryvar, R., Willoughby, K., Gaskell, R.M., Ollier, W.E., Nart, P., Radford, A.D., 2004, Feline leucocyte antigen class II polymorphism and susceptibility to feline infectious peritonitis. J Feline Med Surg 6, 59-62. Addie, D.D., Schaap, I.A., Nicolson, L., Jarrett, O., 2003, Persistence and transmission of natural type I feline coronavirus infection. J Gen Virol 84, 2735-2744. Addie, D.D., Toth, S., Murray, G.D., Jarrett, O., 1995, Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. Am J Vet Res 56, 429-434. Andrew, S.E., 2000, Feline infectious peritonitis. Vet Clin North Am Small Anim Pract 30, 987-1000. Barlough, J.E., Johnson-Lussenburg, C.M., Stoddart, C.A., Jacobson, R.H., Scott, F.W., 1985, Experimental inoculation of cats with human coronavirus 229E and subsequent challenge with feline infectious peritonitis virus. Can J Comp Med 49, 303-307. Barlough, J.E., Scott, F.W., 1990, Effectiveness of three antiviral agents against FIP virus in vitro. Vet Rec 126, 556-558. Barlough, J.E., Stoddart, C.A., Sorresso, G.P., Jacobson, R.H., Scott, F.W., 1984, Experimental inoculation of cats with canine coronavirus and subsequent challenge with feline infectious peritonitis virus. Lab Anim Sci 34, 592-597. Benetka, V., Kubber-Heiss, A., Kolodziejek, J., Nowotny, N., Hofmann-Parisot, M., Mostl, K., 2004, Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet Microbiol 99, 31-42. Can-Sahna, K., Soydal Ataseven, V., Pinar, D., Oguzoglu, T.C., 2007, The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. J Feline Med Surg 9, 369-372. Cave, T.A., Thompson, H., Reid, S.W., Hodgson, D.R., Addie, D.D., 2002, Kitten mortality in the United Kingdom: a retrospective analysis of 274 histopathological examinations (1986 to 2000). Vet Rec 151, 497-501. Chalmers, W.S., Horsburgh, B.C., Baxendale, W., Brown, T.D., 1993, Enhancement of FIP in cats immunised with vaccinia virus recombinants expressing CCV and TGEV spike glycoproteins. Adv Exp Med Biol 342, 359-364. Chomczynski, P., Sacchi, N., 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159. Christianson, K.K., Ingersoll, J.D., Landon, R.M., Pfeiffer, N.E., Gerber, J.D., 1989, Characterization of a temperature sensitive feline infectious peritonitis coronavirus. Arch Virol 109, 185-196. Chu, C.M., Cheng, V.C., Hung, I.F., Wong, M.M., Chan, K.H., Chan, K.S., Kao, R.Y., Poon, L.L., Wong, C.L., Guan, Y., Peiris, J.S., Yuen, K.Y., 2004, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252-256. Colby, E.D., Low, R.J., 1970, Feline infectious peritonitis. Vet Med Small Anim Clin 65, 783-786. Corapi, W.V., Olsen, C.W., Scott, F.W., 1992, Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 66, 6695-6705. Cornelissen, E., Dewerchin, H.L., Van Hamme, E., Nauwynck, H.J., 2007, Absence of surface expression of feline infectious peritonitis virus (FIPV) antigens on infected cells isolated from cats with FIP. Vet Microbiol 121, 131-137. Cresswell, C., Newcombe, A.R., Davies, S., Macpherson, I., Nelson, P., O'Donovan, K., Francis, R., 2005, Optimal conditions for the papain digestion of polyclonal ovine IgG for the production of bio-therapeutic Fab fragments. Biotechnol Appl Biochem 42, 163-168. De Groot, R.J., Andeweg, A.C., Horzinek, M.C., Spaan, W.J., 1988, Sequence analysis of the 3'-end of the feline coronavirus FIPV 79-1146 genome: comparison with the genome of porcine coronavirus TGEV reveals large insertions. Virology 167, 370-376. Dewerchin, H.L., Cornelissen, E., Nauwynck, H.J., 2006, Feline infectious peritonitis virus-infected monocytes internalize viral membrane-bound proteins upon antibody addition. J Gen Virol 87, 1685-1690. Dewerchin, H.L., Cornelissen, E., Van Hamme, E., Smits, K., Verhasselt, B., Nauwynck, H.J., 2008, Surface-expressed viral proteins in feline infectious peritonitis virus-infected monocytes are internalized through a clathrin- and caveolae-independent pathway. J Gen Virol 89, 2731-2740. Duarte, A., Veiga, I., Tavares, L., 2009, Genetic diversity and phylogenetic analysis of Feline Coronavirus sequences from Portugal. Vet Microbiol. Ergonul, O., 2008, Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 78, 125-131. Evermann, J.F., McKeirnan, A.J., Ott, R.L., 1991, Perspectives on the epizootiology of feline enteric coronavirus and the pathogenesis of feline infectious peritonitis. Vet Microbiol 28, 243-255. Evermann, J.F., Roelke, M.E., Briggs, M.B., 1986, Clinical and diagnostic features: feline coronavirus infection of cheetahs. Feline Pract 16, 21-30. Fehr, D., Holznagel, E., Bolla, S., Hauser, B., Herrewegh, A.A., Horzinek, M.C., Lutz, H., 1997, Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine 15, 1101-1109. Gerber, J.D., Ingersoll, J.D., Gast, A.M., Christianson, K.K., Selzer, N.L., Landon, R.M., Pfeiffer, N.E., Sharpee, R.L., Beckenhauer, W.H., 1990, Protection against feline infectious peritonitis by intranasal inoculation of a temperature-sensitive FIPV vaccine. Vaccine 8, 536-542. Haijema, B.J., Volders, H., Rottier, P.J., 2004, Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 78, 3863-3871. Hartmann, K., 2005, Feline infectious peritonitis. Vet Clin North Am Small Anim Pract 35, 39-79. Hartmann, K., Binder, C., Hirschberger, J., Cole, D., Reinacher, M., Schroo, S., Frost, J., Egberink, H., Lutz, H., Hermanns, W., 2003, Comparison of different tests to diagnose feline infectious peritonitis. J Vet Intern Med 17, 781-790. Hartmann, K., Ritz, S., 2008, Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol 123, 172-175. Heeney, J.L., Evermann, J.F., McKeirnan, A.J., Marker-Kraus, L., Roelke, M.E., Bush, M., Wildt, D.E., Meltzer, D.G., Colly, L., Lukas, J., et al., 1990, Prevalence and implications of feline coronavirus infections of captive and free-ranging cheetahs (Acinonyx jubatus). J Virol 64, 1964-1972. Herrewegh, A.A., de Groot, R.J., Cepica, A., Egberink, H.F., Horzinek, M.C., Rottier, P.J., 1995a, Detection of feline coronavirus RNA in feces, tissues, and body fluids of naturally infected cats by reverse transcriptase PCR. J Clin Microbiol 33, 684-689. Herrewegh, A.A., Mahler, M., Hedrich, H.J., Haagmans, B.L., Egberink, H.F., Horzinek, M.C., Rottier, P.J., de Groot, R.J., 1997, Persistence and evolution of feline coronavirus in a closed cat-breeding colony. Virology 234, 349-363. Herrewegh, A.A., Vennema, H., Horzinek, M.C., Rottier, P.J., de Groot, R.J., 1995b, The molecular genetics of feline coronaviruses: comparative sequence analysis of the ORF7a/7b transcription unit of different biotypes. Virology 212, 622-631. Ho, T.Y., Wu, S.L., Chen, J.C., Li, C.C., Hsiang, C.Y., 2007, Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 74, 92-101. Hohdatsu, T., Nakamura, M., Ishizuka, Y., Yamada, H., Koyama, H., 1991, A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies. Arch Virol 120, 207-217. Hohdatsu, T., Okada, S., Ishizuka, Y., Yamada, H., Koyama, H., 1992, The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 54, 557-562. Horsburgh, B.C., Brierley, I., Brown, T.D., 1992, Analysis of a 9.6 kb sequence from the 3' end of canine coronavirus genomic RNA. J Gen Virol 73 ( Pt 11), 2849-2862. Horzinek, M.C., Lutz, H., Pedersen, N.C., 1982, Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses. Infect Immun 37, 1148-1155. Horzinek, M.C., Osterhaus, A.D., 1979, Feline infectious peritonitis: a worldwide serosurvey. Am J Vet Res 40, 1487-1492. Jacobs, L., de Groot, R., van der Zeijst, B.A., Horzinek, M.C., Spaan, W., 1987, The nucleotide sequence of the peplomer gene of porcine transmissible gastroenteritis virus (TGEV): comparison with the sequence of the peplomer protein of feline infectious peritonitis virus (FIPV). Virus Res 8, 363-371. Jakob, H., 1914, Therapeutische, kasuistische und statistische Mitteilungen aus der Klinik fur kleine Haustiere and der Reichstierarzneischule in Utrecht (Holland). Zschr Tiermed 18, 193. Jonsson, C.B., Hooper, J., Mertz, G., 2008, Treatment of hantavirus pulmonary syndrome. Antiviral Res 78, 162-169. Kennedy, M., Citino, S., McNabb, A.H., Moffatt, A.S., Gertz, K., Kania, S., 2002, Detection of feline coronavirus in captive Felidae in the USA. J Vet Diagn Invest 14, 520-522. Keyaerts, E., Vijgen, L., Pannecouque, C., Van Damme, E., Peumans, W., Egberink, H., Balzarini, J., Van Ranst, M., 2007, Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 75, 179-187. Khan, S.H., Goba, A., Chu, M., Roth, C., Healing, T., Marx, A., Fair, J., Guttieri, M.C., Ferro, P., Imes, T., Monagin, C., Garry, R.F., Bausch, D.G., 2008, New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 78, 103-115. Kindt, T.J., Goldspy, R.A., Osborne, B.A., 2007, Cytokines, In: Kindt, T.J., Goldspy, R.A., Osborne, B.A. (Eds.) Kuby Immunology. W. H. Freeman and Coompany, New York, pp. 303-326. Kiss, I., Poland, A.M., Pedersen, N.C., 2004, Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD8. J Feline Med Surg 6, 89-97. Kummrow, M., Meli, M.L., Haessig, M., Goenczi, E., Poland, A., Pedersen, N.C., Hofmann-Lehmann, R., Lutz, H., 2005, Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol 12, 1209-1215. Lai, M.M., 1990, Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol 44, 303-333. Lai, M.M.C., Perlman, S., Anderson, L.J., 2007, Coronaviridae, In: Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., Straus, S.E. (Eds.) Fields virology. Lippincott Wiilliams & Wikins, Philadelphia, pp. 1305-1335. Leyssen, P., De Clercq, E., Neyts, J., 2008, Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78, 9-25. Lin, C.N., Su, B.L., Huang, H.P., Lee, J.J., Hsieh, M.W., Chueh, L.L., 2008, Field strain feline coronaviruses with small deletions in ORF7b associated with both enteric infection and feline infectious peritonitis. J Feline Med Surg. Lin, C.N., Su, B.L., Jan, T.R., Lin, C.T., Chen, C.M., Chueh, L.L., 2009a, Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus in cell culture. (Submitted). Lin, C.N., Su, B.L., Wang, C.H., Hsieh, M.W., Chueh, T.J., Chueh, L.L., 2009b, Genetic diversity and correlation with feline infectious peritonitis of feline coronavirus type I and II: A 5-year study in Taiwan. Vet Microbiol 136, 233-239. Lin, C.N., Su, B.L., Wu, C.W., Hsieh, L.E., Chueh, L.L., 2009c, Isolation and identification of a novel feline coronavirus from a kitten with naturally occurring feline infectious peritonitis in Taiwan. Taiwan Vet J 35 (In press). McArdle, F., Bennett, M., Gaskell, R.M., Tennant, B., Kelly, D.F., Gaskell, C.J., 1992, Induction and enhancement of feline infectious peritonitis by canine coronavirus. Am J Vet Res 53, 1500-1506. Mochizuki, M., Mitsutake, Y., Miyanohara, Y., Higashihara, T., Shimizu, T., Hohdatsu, T., 1997, Antigenic and plaque variations of serotype II feline infectious peritonitis coronaviruses. J Vet Med Sci 59, 253-258. Motokawa, K., Hohdatsu, T., Hashimoto, H., Koyama, H., 1996, Comparison of the amino acid sequence and phylogenetic analysis of the peplomer, integral membrane and nucleocapsid proteins of feline, canine and porcine coronaviruses. Microbiol Immunol 40, 425-433. Olsen, C.W., Corapi, W.V., Ngichabe, C.K., Baines, J.D., Scott, F.W., 1992, Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 66, 956-965. Pedersen, N.C., 1983, Feline infectious peritonitis and feline enteric coronavirus infections. Feline Pract 13, 13-20. Pedersen, N.C., 1987, Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 218, 529-550. Pedersen, N.C., 1995, An overview of feline enteric coronavirus and feline infectious peritonitis virus infection. Feline Pract 23, 7-22. Pedersen, N.C., 2009, A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 11, 225-258. Pedersen, N.C., Black, J.W., 1983, Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 44, 229-234. Pedersen, N.C., Black, J.W., Boyle, J.F., Evermann, J.F., McKeirnan, A.J., Ott, R.L., 1984, Pathogenic differences between various feline coronavirus isolates. Adv Exp Med Biol 173, 365-380. Pedersen, N.C., Boyle, J.F., 1980, Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 41, 868-876. Pedersen, N.C., Boyle, J.F., Floyd, K., Fudge, A., Barker, J., 1981, An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res 42, 368-377. Pedersen, N.C., Ward, J., Mengeling, W.L., 1978, Antigenic relationship of the feline infections peritonitis virus to coronaviruses of other species. Arch Virol 58, 45-53. Povey, R.C., 1978, In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am J Vet Res 39, 175-178. Powderly, W.G., Tebas, P., 1999, Nelfinavir, a new protease inhibitor: early clinical results. AIDS 13 Suppl 1, S41-48. Reed, L.J., Muench, H.A., 1938, A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493-497. Reeves, N.C., Pollock, R.V., Thurber, E.T., 1992, Long-term follow-up study of cats vaccinated with a temperature-sensitive feline infectious peritonitis vaccine. Cornell Vet 82, 117-123. Reiser, M., Salzberger, B., Stiepel, A., Hoetelmans, R., Diehl, V., Fatkenheuer, G., 1999, Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Eur J Med Res 4, 54-58. Ritz, S., Egberink, H., Hartmann, K., 2007, Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med 21, 1193-1197. Rohrer, C.R., Suter, P., Lutz, H., 1993, Feline infectious peritonitis (FIP): a retrospective and prospective study. Kleintierprax 38, 379-389. Shiba, N., Maeda, K., Kato, H., Mochizuki, M., Iwata, H., 2007, Differentiation of feline coronavirus type I and II infections by virus neutralization test. Vet Microbiol 124, 348-352. Sourial, S., Nilsson, C., 2008, HIV-2 neutralization by intact V3-specific Fab fragments. Virol J 5, 96. Sparkes, A.H., Gruffydd-Jones, T.J., Harbour, D.A., 1992, Feline coronavirus antibodies in UK cats. Vet Rec 131, 223-224. Starr, S.E., Fletcher, C.V., Spector, S.A., Yong, F.H., Fenton, T., Brundage, R.C., Manion, D., Ruiz, N., Gersten, M., Becker, M., McNamara, J., Mofenson, L.M., Purdue, L., Siminski, S., Graham, B., Kornhauser, D.M., Fiske, W., Vincent, C., Lischner, H.W., Dankner, W.M., Flynn, P.M., 1999, Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 341, 1874-1881. Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins, R.K., Simon, L.N., 1973, Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A 70, 1174-1178. Takano, T., Azuma, N., Hashida, Y., Satoh, R., Hohdatsu, T., 2009, B-cell activation in cats with feline infectious peritonitis (FIP) by FIP-virus-induced B-cell differentiation/survival factors. Arch Virol 154, 27-35. Takano, T., Hohdatsu, T., Hashida, Y., Kaneko, Y., Tanabe, M., Koyama, H., 2007a, A 'possible' involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet Microbiol 119, 121-131. Takano, T., Hohdatsu, T., Toda, A., Tanabe, M., Koyama, H., 2007b, TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 364, 64-72. Takano, T., Katada, Y., Moritoh, S., Ogasawara, M., Satoh, K., Satoh, R., Tanabe, M., Hohdatsu, T., 2008, Analysis of the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection: aminopeptidase N is not important and a process of acidification of the endosome is necessary. J Gen Virol 89, 1025-1029. Tan, E.L., Ooi, E.E., Lin, C.Y., Tan, H.C., Ling, A.E., Lim, B., Stanton, L.W., 2004, Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10, 581-586. Vennema, H., 1999, Genetic drift and genetic shift during feline coronavirus evolution. Vet Microbiol 69, 139-141. Vennema, H., de Groot, R.J., Harbour, D.A., Dalderup, M., Gruffydd-Jones, T., Horzinek, M.C., Spaan, W.J., 1990, Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64, 1407-1409. Vennema, H., Poland, A., Foley, J., Pedersen, N.C., 1998, Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 243, 150-157. Vennema, H., Rossen, J.W., Wesseling, J., Horzinek, M.C., Rottier, P.J., 1992, Genomic organization and expression of the 3' end of the canine and feline enteric coronaviruses. Virology 191, 134-140. Watt, N.J., MacIntyre, N.J., McOrist, S., 1993, An extended outbreak of infectious peritonitis in a closed colony of European wildcats (Felis silvestris). J Comp Pathol 108, 73-79. Weiss, R.C., Cox, N.R., Boudreaux, M.K., 1993a, Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 16, 301-316. Weiss, R.C., Cox, N.R., Martinez, M.L., 1993b, Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet Sci 55, 162-172. Weiss, R.C., Cox, N.R., Oostrom-Ram, T., 1990, Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res 51, 726-733. Weiss, R.C., Oostrom-Ram, T., 1989, Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 20, 255-265. Weiss, R.C., Toivio-Kinnucan, M., 1988, Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. Am J Vet Res 49, 1329-1335. Woo, P.C., Wang, M., Lau, S.K., Xu, H., Poon, R.W., Guo, R., Wong, B.H., Gao, K., Tsoi, H.W., Huang, Y., Li, K.S., Lam, C.S., Chan, K.H., Zheng, B.J., Yuen, K.Y., 2007, Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol 81, 1574-1585. Woods, R.D., Pedersen, N.C., 1979, Cross-protection studies between feline infectious peritonitis and porcine transmissible gastroenteritis virus. Vet Microbiol 4, 11-16. Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Doerr, H.W., Hunsmann, G., Otaka, A., Tamamura, H., Fujii, N., 2004, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318, 719-725. Zook, B.C., King, N.W., Robison, R.L., McCombs, H.L., 1968, Ultrastructural evidence for the viral etiology of feline infectious peritonitis. Pathol Vet 5, 91. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43988 | - |
| dc.description.abstract | 貓傳染性腹膜炎 (Feline infectious peritonitis, FIP) 為由貓冠狀病毒 (Feline coronaviurs, FCoV) 所引起之免疫媒介、高度致死性疾病，目前為尚無有效之治療方法。本研究之目的為探討利用豬抗冠狀病毒血清及部份上市之抗病毒藥物對清除FCoV感染及控制FIP之可能性。以表現重組豬傳染性胃腸炎病毒 (Transmissible gastroenteritis virus, TGEV) spike protein之痘病毒免疫無特定病原 (Specific pathogen free, SPF) 豬隻之血清作為抗血清。進行其對FCoV中和試驗評估，結果顯示其抗第二型FCoV中和抗體力價為1024倍，接近FIP貓的抗體力價平均值。抗病毒藥物實驗中，首先於fcwf-4細胞中以MTT試驗評估11個藥物之細胞毒性，選取細胞毒性小於5%之藥物濃度，以計算細胞病變效應病灶 (Cytopathic effect loci, CPE loci) 進行抗病毒效力之篩選，結果顯示，所有藥物於測試濃度皆無法有效抑制病毒複製。若選取此11個藥物細胞毒性小於20%之濃度分別與本實驗室先前證實具抗病毒效應之藥物nelfinavir合併使用，結果發現與單獨給予nelfinavir 6.25 μg/ml 相比，nelfinavir 6.25 μg/ml 合併不同濃度ribavirin顯現具有加乘之抗病毒效應 (Synergistic antiviral effect)，而能顯著降低上清液之病毒力價同時對細胞毒性亦未增加。於本實驗中觀察到豬抗TGEV spike protein血清及ribavirin/ nelfinavir之合併使用於體外試驗中具有抑制FCoV複製之活性，或有更進一步運用於臨床FIP預防及控制之可行性。 | zh_TW |
| dc.description.abstract | Feline infectious peritonitis (FIP), is an immune-mediated fatal disease caused by feline coronavirus (FCoV). Currently no effective vaccine and therapy is available for the disease. This study aims to evaluate the possibility of using swine anti-coronaviral serum and other new antiviral agents as a mean for the prevention and control of FIP. Serum harvested from specific pathogen free (SPF) pigs inoculated with vaccinia virus expressing recombinant transmissible gastroenteritis virus (TGEV) spike protein were tested for its neutralization capacity against FCoV. The result showed this swine origin anti-coronaviral serum exhibited the ability to neutralize FCoV type II to a relative high neutralizing titer (1024 ×). A titer that is nearly reach the mean of those serum obtained from other naturally occurring FIP. In the evaluation of inhibitory activity of antiviral agents, the cytotoxicity of 11 commercialized antiviral agents was first tested by MTT assay on fcwf-4 cell. Based on the results of MTT assay, the highest concentration of every agents with less than 5% of cytotoxicity were determined for further antiviral screening by counting of Cytopathic effect loci (CPE loci). None of the 11 antiviral agents tested showed reduction of CPE loci. Whether these agents can inhibit replication of FCoV when combined with nelfinavir, the agent that has been proven to be effective against FCoV, was further tested. The results showed 6.25 μg/ml of nelfinavir combined with 50 μg/ml and 25 μg/ml of ribavirin exhibited significant inhibitory effect. Taken together, swine anti-TGEV spike protein serum alone and combined use of 2 antiviral agents, i.e. ribavirin and nelfinavir, showed inhibitory effect against FCoV in vitro. These agents will have potential in the future clinical application for the prevention and control of FIP. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:35:17Z (GMT). No. of bitstreams: 1 ntu-98-R96629033-1.pdf: 4431832 bytes, checksum: 348001ee48ed9fb062b4bcc52861cd0f (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 目錄 ---------------------------------------------------------------------------------------------- I
圖次----------------------------------------------------------------------------------------------- V 表次 ---------------------------------------------------------------------------------------------- VI 中文摘要 ---------------------------------------------------------------------------------------- VII 英文摘要 ----------------------------------------------------------------------------------------VIII 第一章 序言 ------------------------------------------------------------------------------------ 1 第二章 文獻探討 ------------------------------------------------------------------------------ 3 第一節 歷史背景 ----------------------------------------------------------------------- 3 第二節 病毒特徵 ----------------------------------------------------------------------- 3 2.1.1 病毒分類 ------------------------------------------------------------ 3 2.1.2 基因體特性 --------------------------------------------------------- 4 2.1.3 貓冠狀病毒之分型 ------------------------------------------------ 6 2.2 宿主 --------------------------------------------------------------------------- 7 第三節 貓冠狀病毒與疾病 ----------------------------------------------------------- 7 3.1 流行病學、致病機制及免疫反應 --------------------------------------- 7 3.1.1 流行病學 ------------------------------------------------------------ 8 3.1.2 致病機制 ------------------------------------------------------------ 8 3.1.3 免疫反應 ------------------------------------------------------------ 9 3.2 臨床症狀與診斷 ------------------------------------------------------------ 11 3.2.1 臨床症狀 ------------------------------------------------------------ 11 3.2.2 診斷 ------------------------------------------------------------------ 11 3.3 治療及預防 ------------------------------------------------------------------ 12 3.3.1 臨床上之治療 ------------------------------------------------------ 12 3.3.2 預防與控制 --------------------------------------------------------- 14 第三章 材料與方法 --------------------------------------------------------------------------- 16 第一節 病毒確認及定量 -------------------------------------------------------------- 16 3.1.1 細胞及病毒 --------------------------------------------------------- 16 3.1.2 RNA萃取 ------------------------------------------------------------ 16 3.1.3 反轉錄反應 --------------------------------------------------------- 17 3.1.4 聚合酶鍊鎖反應 --------------------------------------------------- 17 3.1.5 電泳分析 ------------------------------------------------------------ 18 3.1.6 病毒斑試驗 --------------------------------------------------------- 18 3.1.7 間接免疫螢光染色 ------------------------------------------------ 19 第二節 抗血清效力之體外評估 ----------------------------------------------------- 19 3.2.1 血清 ------------------------------------------------------------------ 19 3.2.2 血清中和試驗 ------------------------------------------------------ 19 第三節 抗病毒藥物效力之體外評估 ----------------------------------------------- 20 3.3.1 抗病毒藥物 --------------------------------------------------------- 20 3.3.2 細胞活性 ------------------------------------------------------------ 20 3.3.3 抗病毒效應之篩選 ------------------------------------------------ 21 3.3.4 抗病毒藥物與nelfinavir合併給予之抗病毒效應篩選 ------ 21 3.3.5 評估抗病毒藥物與nelfinaivr合併給予之抗病毒效應 ------ 22 3.3.6 Ribavirin合併nelfinaivr之細胞活性 ---------------------------- 22 3.3.7 濃度相關性抗病毒效應 ------------------------------------------ 22 3.3.8 統計分析 ------------------------------------------------------------ 22 第四章 結果 ------------------------------------------------------------------------------------ 23 第一節 病毒確認及定量 -------------------------------------------------------------- 23 4.1.1 病毒核酸之確認 --------------------------------------------------- 23 4.1.2 病毒力價 ------------------------------------------------------------ 23 4.1.3 間接免疫螢光染色 ------------------------------------------------ 23 第二節 抗血清效力之體外評估 ----------------------------------------------------- 23 4.2.1 血清中和試驗 ------------------------------------------------------ 23 第三節 抗病毒藥物效力之體外評估 ----------------------------------------------- 24 4.3.1 藥物之細胞毒性評估 --------------------------------------------- 24 4.3.2 抗病毒藥物之篩選 ------------------------------------------------ 24 4.3.3 抗病毒藥物合併nelfinaivr給予抗病毒效果之評估 --------- 24 4.3.4 Ribavirin與nelfinavir合併給予抗病毒效果之評估 ---------- 25 4.3.5 Ribavirin與nelfinavir合併給予之細胞毒性 ------------------- 25 4.3.6 濃度相關性抗病毒效應 ------------------------------------------ 25 第五章 討論 ----------------------------------------------------------------------------------- 27 附圖 ---------------------------------------------------------------------------------------------- 33 附表 ---------------------------------------------------------------------------------------------- 43 參考文獻 ---------------------------------------------------------------------------------------- 47 | |
| dc.language.iso | zh-TW | |
| dc.title | 豬抗冠狀病毒血清及抗病毒藥物對貓冠狀病毒生長抑制效應之體外評估 | zh_TW |
| dc.title | Inhibitory effect of swine anti-coronaviral serum and antiviral agents against feline coronavirus in vitro | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 闕玲玲 | |
| dc.contributor.oralexamcommittee | 陳啟銘,詹東榮,蘇璧伶 | |
| dc.subject.keyword | 貓冠狀病毒,抗血清,抗病毒藥物,抗病毒,體外, | zh_TW |
| dc.subject.keyword | Feline coronavirus,FCoV,Antiserum,Antiviral agents,Antiviral drugs,Antiviral,in vitro, | en |
| dc.relation.page | 60 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-13 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 目前未授權公開取用 | 4.33 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。